Skip to content

Effect of Drug Therapy vs Arthroscopic Partial Meniscectomy in Patients With Degenerative Meniscal Tears

Effect of Drug Therapy vs Arthroscopic Partial Meniscectomy in Patients With Degenerative Meniscal Tears

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079330
Enrollment
Unknown
Registered
2023-12-31
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative meniscus tear

Interventions

intervention group:An arthroscopic partial excision will be performed by experienced orthopedic surgeon. Damaged meniscus will be trimmed to a stable edge. The cartilage will be trimmed appropriately
control group:25mg sodium hyaluronate injection into the joint cavity of the affected limb by experienced orthopaedic surgeon weekly for 5 weeks.

Sponsors

The Seventh Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) The patient was between 45 and 70 years old at the time of presentation. 2) Meniscus tear can be seen on MRI. 3) Sound mind. 4) Willingness to follow the follow-up plan. 5) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Acute surgery due to knee interlock or trauma. 2) One of the tested knee joints has the following related injuries: a. Symptomatic partial ACL tear or any complete ACL tear as determined by clinical examination (positive Lachman test and/or positive Pivot Shift) with an MRI indicating ACL injury; b. Complete PCL injury; c. Cartilaginous changes; Level 4 of the Kellgren Lawrence Scale of osteoarthritis, visible on X-ray; d. Lateral/posterolateral ligament complex injury, significantly increased relaxation. 3) Other surgical history of the subject's knee joint, other than diagnostic arthroscopy. 4) Tumor suspected to be malignant on MRI. 5) Obese patients with BMI>35. 6) Patients with ASA 4-5 (Appendix D), which may interfere with recovery. 7) General diseases that affect physical function or systemic drug/steroid abuse (e.g. Rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout, pseudogout). 8) Any other medical conditions or treatments that may interfere with the completion or evaluation of the trial, such as contraindications to MRI or surgery. 9) Drug or alcohol abuse. 10) Patients who cannot speak or read Chinese.

Design outcomes

Primary

MeasureTime frame
Intemational Knee Documentation Committee Knee Form, IKDC;

Secondary

MeasureTime frame
general health;life quality; knee pain;activity level;Patient-specific complaint;physical examination;progression of osteoarthritis;expectation;meniscus condition;adverse event;satisfaction;

Countries

China

Contacts

Public ContactXu Chen

The Seventh Affiliated Hospital, Sun Yat-sen University

chenxu0041@126.com+86 186 4088 3997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026